Marshall Wace, LLP Corvus Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 74,559 shares of CRVS stock, worth $383,978. This represents 0.0% of its overall portfolio holdings.
Number of Shares
74,559Holding current value
$383,978% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding CRVS
# of Institutions
52Shares Held
28MCall Options Held
22.9KPut Options Held
29.8K-
Orbimed Advisors LLC San Diego, CA6.94MShares$35.8 Million0.3% of portfolio
-
Samlyn Capital, LLC New York, NY6.12MShares$31.5 Million0.2% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.96MShares$30.7 Million0.03% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$16.9 Million2.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$8.5 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $240M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...